Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Alteogen executed an exclusive license agreement with Daiichi Sankyo for the development and commercialization of a subcutaneous (SC) formulation of the ADC therapy Enhertu® using ALT-B4 technology, featuring an upfront payment of approx. KRW 28.0B and milestones up to approx. KRW 391.7B.
📊 [Key Disclosure Details & Financial Highlights]
- Contracting Party: Daiichi Sankyo (Japan, Recent Annual Revenue: JPY 1,601,688M)
- Scope of Agreement: Exclusive license for the development and commercialization of a subcutaneous (SC) formulation of the ADC therapy Enhertu® utilizing Alteogen’s Hybrozyme platform (ALT-B4)
- Agreement Date & Term: 2024-11-08 ~ Until expiration of the royalty period
- Key Financial Terms (FX Rate: 1,399.1 KRW/USD):
- Upfront Fee: USD 20,000,000 (Approx. KRW 27.98B / 28.99% of recent annual consolidated revenue)
- To be received within 30 days of execution (by 2024-12-08, non-refundable)
- Milestones: Up to USD 280,000,000 (Approx. KRW 391.75B)
- Payable upon achieving clinical, regulatory approval, and sales targets
- Total Maximum Considerations (Upfront + Milestones): USD 300,000,000 (Approx. KRW 419.73B, sales royalties separate)
- Sales Royalties: Running royalties based on a percentage of net sales upon commercialization
- Upfront Fee: USD 20,000,000 (Approx. KRW 27.98B / 28.99% of recent annual consolidated revenue)
- Investment Risks & Regulatory Notes:
- Conditional agreement dependent on clinical trial success and regulatory approvals (FDA, MFDS, etc.)
- Received upfront fees, milestones, and royalties carry no refund obligation
- Detailed breakdown of milestone steps and royalty percentages is under disclosure deferral until 2041-12-31 per confidentiality terms
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verifying Upfront Receipt and Milestone Progress
This filing confirms the execution of a key technology export agreement for the subcutaneous formulation of the ADC drug Enhertu®. Verifying the receipt of the USD 20M upfront payment within the scheduled 30-day period (by December 8, 2024) and tracking subsequent clinical trial advancements or regulatory milestone recognitions by Daiichi Sankyo is important to monitor the actual financial realization of the deal. Further progress can be tracked through future disclosures and upcoming periodic reports.
📢 Disclaimer & Source Information
Source: This content was structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For inquiries regarding regulatory compliance or copyright requests, please contact ksb220805@gmail.com.
